

## Meeting Minutes: Drug Formulary Committee

Date & Time: February 5, 2019; 5:30-9 PM  
Minutes prepared by: Hind Douiki and Dave Hoang  
Location: Elmer Andersen Building, Room 2370, 540 Cedar Street, St. Paul, MN 55101

### Attendance

---

- Members in attendance: Kyle Lehenbauer, M.D.; Stacey Ness, Pharm.D.; Kelly Ruby, Pharm.D.; Michael Sprehe, M.D.; Stuart Williams, J.D.; Monica Brands, R.Ph; James Phillips, M.D.; Margaret Artz, R.Ph., Ph.D.; Mary Mescher Benbenek, APRN, Ph.D.
- Members absent: Al Heaton, R.Ph; Kathryn Lombardo, M.D.; Ramona Powell, Pharm.D.
- DHS staff present: Jeff Schiff, M.D., MBA; Chad Hope, Pharm.D.; Dave Hoang, Pharm.D., MBA; Mary Beth Reinke, Pharm.D., MSA.; Sharon Feinstein-Rosenblum PharmD
- Others in attendance: Hind Douiki, Pharm.D.; Ariane Casey, Pharm.D.

### Report of the Chair

---

No new report

### Approval of Minutes

---

Minutes from the December 2018 meeting were reviewed and approved.

### DHS Housekeeping

---

- Dave Hoang introduced two new DFC members (Mary Mescher Benbenek APRN, Ph.D who was present and another member who was absent from the meeting).
- Dave Hoang informed the DFC members that an annual ethics training will be made available to DFC members and DFC members should complete a conflict of interest disclosure at least annually.

### Old Business

---

#### Existing Specialty Drugs for Continued PA

- The committee discussed Humira for Uveitis and recommended to the department by a unanimous vote that Humira remain on PA.

## New Business

---

- Dr. Ness made the motion to move up Prior Authorization Criteria in the agenda before Preferred Drug List. There were no objections to the motion.

### Prior Authorization Criteria

1. Continuation of Therapy
  - The committee discussed Continuation of Therapy PA Criteria. Dave provided an overview of the MN MCOs reasons to support requiring attestation, as well as an overview of the MN MCOs reasons to support requiring documentation. The committee recommended to the department by a unanimous vote that Continuation of Therapy PA, is implemented as proposed, with 90-day approval duration, and with requirement of attestation (with further evaluation of its effectiveness).
2. Non-Preferred Drugs
  - The committee discussed Non-Preferred Drugs PA Criteria. Dave provided an overview of the MN MCOs reasons to support requiring attestation, as well as an overview of the MN MCOs reasons to support requiring documentation. The committee recommended to the department by a unanimous vote that Non-Preferred Drugs PA, is implemented as proposed, with requirement of documentation.

### Preferred Drug List

- DHS FFS PDL is posted at: [https://mn.gov/dhs/assets/preferred-drug-list-fee-for-service\\_tcm1053-292127.pdf](https://mn.gov/dhs/assets/preferred-drug-list-fee-for-service_tcm1053-292127.pdf)
- Dave indicated that at this meeting the committee will review the top 10 therapeutic classes in terms of spend for traditional and specialty drugs.
- The committee discussed the Antipsychotics therapeutic class and recommended to the department by a unanimous vote that the preferred and non-preferred Antipsychotics drugs remain as they are presented on the PDL document dated January 11, 2019.
- The committee discussed the Stimulants and Related Agents therapeutic class and recommended to the department by a unanimous vote that the preferred and non-preferred Stimulants and Related Agents drugs remain as they are presented on the PDL document dated January 11, 2019.
- The committee discussed the Anticonvulsants therapeutic class and recommended to the department by a unanimous vote that the preferred and non-preferred Anticonvulsants drugs remain as they are presented on the PDL document dated January 11, 2019.
- The committee discussed the Neuropathic Pain therapeutic class and recommended to the department by a unanimous vote that the preferred and non-preferred Neuropathic Pain drugs remain as they are presented on the PDL document dated January 11, 2019, with the removal of the words “Cymbalta Gen.” next to duloxetine.
- The committee discussed the Short Acting Narcotics therapeutic class and recommended to the department by a unanimous vote that the statement regarding preferred Short Acting Narcotics drugs, as well as the list of non-preferred Short Acting Narcotics drugs remain as they are presented on the PDL document dated January 11, 2019.
- The committee discussed the Opiate Dependence Treatments therapeutic class and recommended to the department by a unanimous vote that the preferred and non-preferred Opiate Dependence Treatments drugs remain as they are presented on the PDL document dated January 11, 2019.

- The committee discussed the Epinephrine Self-Injected therapeutic class and recommended to the department by a unanimous vote that the preferred and non-preferred Epinephrine Self-Injected drugs remain as they are presented on the PDL document dated January 11, 2019.
- The committee discussed the Inhaled Glucocorticoids therapeutic class and recommended to the department by a unanimous vote that the preferred and non-preferred Inhaled Glucocorticoids drugs remain as they are presented on the PDL document dated January 11, 2019.
- The committee discussed the Hepatitis C therapeutic class and recommended to the department by a unanimous vote that the preferred and non-preferred Hepatitis C drugs remain as they are presented on the PDL document dated January 11, 2019, with the addition of the Harvoni and Eplclusa Authorized Generics to the non-preferred list.
- The committee discussed the Cytokine and CAM Antagonists therapeutic class and recommended to the department by a unanimous vote that the preferred and non-preferred Cytokine and CAM Antagonists drugs remain as they are presented on the PDL document dated January 11, 2019.

## Adjournment

---

- The meeting was adjourned at approximately 8:31 PM Central Time.